M
Myriad Genetics D
D
MYGN
3.21000
USD
0.07
(2.07%)
Market Closed
Volume
46,746
EPS
-0
Div Yield
-
P/E
-3
Market Cap
307,035,360
Articles
Title: Myriad Genetics
Sector: Healthcare
Industry: Diagnostics & Research
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.



